tiprankstipranks
Trending News
More News >
Croda International PLC (GB:50GP)
LSE:50GP
UK Market

Croda International (50GP) Earnings Dates, Call Summary & Reports

Compare
0 Followers

Earnings Data

Report Date
Jul 29, 2026
TBA (Not Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 24, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call balanced encouraging operational and financial progress—7% sales growth, improved adjusted profits, stronger free cash flow, margin recovery and clear multi-year targets—against meaningful near-term headwinds including large exceptional impairments (GBP 150m), noncash write-offs, Industrial Specialties weakness, FX and inflation pressures, and transformation costs/risks. Management presented a detailed plan (GBP 100m savings, SKU/customer rationalization, supply‑chain optimization) and conservative guidance that assumes breakout pharma projects are excluded from the near-term targets. Overall the positives around growth, cash generation, portfolio positioning and a defined transformation pipeline outweigh the challenges, while the impairments and execution risk warrant ongoing monitoring.
Company Guidance
Management guided adjusted operating profit to be in line with market expectations and reiterated organic sales growth of 3–6% p.a. for Consumer Care (4–7% for Life Sciences), a group average of 3–6% to 2028, with Q1 expected broadly flat versus the strong Q1 2025 and H1/H2 splitting roughly 50/50. They target adjusted operating margin >20% by 2028 (EBITDA margin >25%), free cash flow conversion >12% of sales, GBP100m annualized transformation savings (GBP80m cash cost; ~GBP75m still to come), working capital reduction of GBP50m, CapEx around ~GBP108m (~6% of sales), net debt maintained in the 1–2x EBITDA range (current net debt £524m; leverage 1.3x), a dividend policy of 40–50% of adjusted earnings (current payout ~76% with FY dividend 111p), disciplined M&A (bolt‑ons typically <£10m), and continued focus on price/mix improvement and volume recovery (volumes to moderate from 10% in 2025).
Full-Year Sales Growth
Sales grew 7% in constant currency to GBP 1.7 billion for FY2025, with Q4 sales up 5% cc versus a strong comparator.
Adjusted Profit and EBITDA Expansion
Adjusted operating profit rose 8% to GBP 295 million and adjusted profit before tax increased 8% to GBP 276 million; EBITDA increased 5% to GBP 397 million.
Segment Outperformance – Consumer Care & F&F
Consumer Care grew 8% for the year and 9% in Q4; Fragrances & Flavors (F&F) was a standout, up ~15% for the year with strong regional/local customer demand.
Life Sciences and Crop Momentum
Life Sciences grew 8% for the year with Crop Protection up 14% (full year) and Seed Enhancement up 8%; Pharma delivered its strongest quarter, driven by higher excipient sales.
Innovation and Pipeline Progress
Sales of patented ingredients rose 9%; sales of new ingredients increased 10% in 2025 and average pipeline value per customer co-creation project increased 12%.
Improved Customer Metrics
Net Promoter Score improved by 11 points, with >90% customer retention over 5 years and top-quartile benchmarking for product quality, innovation and trust.
Margin Recovery and Transformation Benefit
Operating margin improved through the year (17.2% → 17.4% full year; second-half margin 17.6%) with a 1.6 percentage point benefit cited from transformation cost savings.
Free Cash Flow and Leverage
Free cash flow strengthened to GBP 162 million in FY2025; net debt reduced slightly to GBP 524 million with leverage improving to 1.3x EBITDA.
CapEx Discipline
CapEx reduced from GBP 138 million to GBP 108 million (below guidance of GBP 135 million), with a planned continuation around ~6% of sales.
Clear 3-Year Financial Framework
Management targets organic sales growth of c.3–6% (Consumer Care) and 4–7% (Life Sciences), adjusted operating margin >20% by 2028, free cash flow conversion >12% and ROIC >10%, plus GBP 100 million annualized transformation savings and GBP 50 million working capital reduction by 2028.

Croda International (GB:50GP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:50GP Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 29, 2026
2026 (Q2)
- / -
Feb 24, 2026
2025 (Q4)
- / -
Jul 29, 2025
2025 (Q2)
- / -
Feb 25, 2025
2024 (Q4)
- / -
Jul 30, 2024
2024 (Q2)
- / -
Feb 27, 2024
2023 (Q4)
- / -
Jul 25, 2023
2023 (Q2)
- / -
Feb 28, 2023
2022 (Q4)
- / -
Jul 29, 2022
2022 (Q2)
- / -
Mar 01, 2022
2021 (Q4)
- / -
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:50GP Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 24, 2026
83.00p83.00p0.00%
Jul 29, 2025
78.00p78.00p0.00%
Feb 25, 2025
83.00p83.00p0.00%
Jul 30, 2024
78.12p78.12p0.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Croda International PLC (GB:50GP) report earnings?
Croda International PLC (GB:50GP) is schdueled to report earning on Jul 29, 2026, TBA (Not Confirmed).
    What is Croda International PLC (GB:50GP) earnings time?
    Croda International PLC (GB:50GP) earnings time is at Jul 29, 2026, TBA (Not Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Croda International PLC stock?
          The P/E ratio of Croda International is N/A.
            What is GB:50GP EPS forecast?
            Currently, no data Available